APO Research
Talk to an analyst

APO RESEARCH · REPORT

Tumor Radioimmunotherapy

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Tumor Radioimmunotherapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

28 December 2025195 pages

Choose your research edition.

Industry ResearchTumor Radioimmunotherapy Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal Tumor Radioimmunotherapy Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Tumor Radioimmunotherapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Tumor Radioimmunotherapy Market Outlook and Growth Opportunities 2026205 pages · $4,250 USDMarket Analysis & ForecastGlobal Tumor Radioimmunotherapy Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

The global Tumor Radioimmunotherapy market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Tumor Radioimmunotherapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Tumor Radioimmunotherapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Tumor Radioimmunotherapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Tumor Radioimmunotherapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Tumor Radioimmunotherapy include Novartis, Bayer, Y-mAbs Therapeutics, Telix Pharmaceuticals, RadioMedix, Philogen, Orano Med, Nordic Nanovector and Mundipharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Tumor Radioimmunotherapy market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Tumor Radioimmunotherapy and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Tumor Radioimmunotherapy revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Tumor Radioimmunotherapy market size, projected growth trends, production technologies, key applications, and end-use industries.

Tumor Radioimmunotherapy Segment by Company

Novartis

Bayer

Y-mAbs Therapeutics

Telix Pharmaceuticals

RadioMedix

Philogen

Orano Med

Nordic Nanovector

Mundipharma

Lantheus

Gilead Sciences

Fusion Pharmaceuticals

Curium Pharmaceuticals

Curasight

Clarity Pharmaceuticals

China Isotope & Radiation

Aurobindo Pharma

Actinium Pharmaceuticals

Tumor Radioimmunotherapy Segment by Type

Beta-emitting

Targeted Alpha Therapy

Tumor Radioimmunotherapy Segment by Application

Solid Tumor

Non Hodgkin Lymphoma

Tumor Radioimmunotherapy Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tumor Radioimmunotherapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Tumor Radioimmunotherapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tumor Radioimmunotherapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Tumor Radioimmunotherapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Tumor Radioimmunotherapy industry.

Chapter 3: Detailed analysis of Tumor Radioimmunotherapy companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Tumor Radioimmunotherapyrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Tumor Radioimmunotherapy Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Beta-emitting Table 3. Key Players of Targeted Alpha Therapy Table 4. Global Tumor Radioimmunotherapy Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of Solid Tumor Table 6. Key Players of Non Hodgkin Lymphoma Table 7. Global Tumor Radioimmunotherapy Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 8. Global Tumor Radioimmunotherapy Market Size by Region (2021-2026) & (US$ Million) Table 9. Global Tumor Radioimmunotherapy Market Share by Region (2021-2026) Table 10. Global Tumor Radioimmunotherapy Market Size by Region (2027-2032) & (US$ Million) Table 11. Global Tumor Radioimmunotherapy Market Share by Region (2027-2032) Table 12. Tumor Radioimmunotherapy Industry Trends Table 13. Tumor Radioimmunotherapy Industry Drivers Table 14. Tumor Radioimmunotherapy Industry Opportunities and Challenges Table 15. Tumor Radioimmunotherapy Industry Restraints Table 16. Global Tumor Radioimmunotherapy Revenue by Company (US$ Million) & (2021-2026) Table 17. Global Tumor Radioimmunotherapy Revenue Market Share by Company (2021-2026) Table 18. Global Tumor Radioimmunotherapy Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 19. Global Tumor Radioimmunotherapy Key Company Head Office and Area Served Table 20. Global Tumor Radioimmunotherapy Company, Product Type & Application Table 21. Global Tumor Radioimmunotherapy Company Establishment Date Table 22. Global Company Market Concentration Ratio (CR5 and HHI) Table 23. Global Tumor Radioimmunotherapy by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 24. Global Tumor Radioimmunotherapy Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Tumor Radioimmunotherapy Market Size by Type (2021-2026) & (US$ Million) Table 26. Global Tumor Radioimmunotherapy Market Size by Type (2027-2032) & (US$ Million) Table 27. Global Tumor Radioimmunotherapy Revenue Market Share by Type (2021-2026) Table 28. Global Tumor Radioimmunotherapy Revenue Market Share by Type (2027-2032) Table 29. Global Tumor Radioimmunotherapy Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Tumor Radioimmunotherapy Market Size by Application (2021-2026) & (US$ Million) Table 31. Global Tumor Radioimmunotherapy Market Size by Application (2027-2032) & (US$ Million) Table 32. Global Tumor Radioimmunotherapy Revenue Market Share by Application (2021-2026) Table 33. Global Tumor Radioimmunotherapy Revenue Market Share by Application (2027-2032) Table 34. Novartis Company Information Table 35. Novartis Business Overview Table 36. Novartis Tumor Radioimmunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 37. Novartis Tumor Radioimmunotherapy Product Portfolio Table 38. Novartis Recent Development Table 39. Bayer Company Information Table 40. Bayer Business Overview Table 41. Bayer Tumor Radioimmunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Bayer Tumor Radioimmunotherapy Product Portfolio Table 43. Bayer Recent Development Table 44. Y-mAbs Therapeutics Company Information Table 45. Y-mAbs Therapeutics Business Overview Table 46. Y-mAbs Therapeutics Tumor Radioimmunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Y-mAbs Therapeutics Tumor Radioimmunotherapy Product Portfolio Table 48. Y-mAbs Therapeutics Recent Development Table 49. Telix Pharmaceuticals Company Information Table 50. Telix Pharmaceuticals Business Overview Table 51. Telix Pharmaceuticals Tumor Radioimmunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Telix Pharmaceuticals Tumor Radioimmunotherapy Product Portfolio Table 53. Telix Pharmaceuticals Recent Development Table 54. RadioMedix Company Information Table 55. RadioMedix Business Overview Table 56. RadioMedix Tumor Radioimmunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. RadioMedix Tumor Radioimmunotherapy Product Portfolio Table 58. RadioMedix Recent Development Table 59. Philogen Company Information Table 60. Philogen Business Overview Table 61. Philogen Tumor Radioimmunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Philogen Tumor Radioimmunotherapy Product Portfolio Table 63. Philogen Recent Development Table 64. Orano Med Company Information Table 65. Orano Med Business Overview Table 66. Orano Med Tumor Radioimmunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. Orano Med Tumor Radioimmunotherapy Product Portfolio Table 68. Orano Med Recent Development Table 69. Nordic Nanovector Company Information Table 70. Nordic Nanovector Business Overview Table 71. Nordic Nanovector Tumor Radioimmunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. Nordic Nanovector Tumor Radioimmunotherapy Product Portfolio Table 73. Nordic Nanovector Recent Development Table 74. Mundipharma Company Information Table 75. Mundipharma Business Overview Table 76. Mundipharma Tumor Radioimmunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. Mundipharma Tumor Radioimmunotherapy Product Portfolio Table 78. Mundipharma Recent Development Table 79. Lantheus Company Information Table 80. Lantheus Business Overview Table 81. Lantheus Tumor Radioimmunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. Lantheus Tumor Radioimmunotherapy Product Portfolio Table 83. Lantheus Recent Development Table 84. Gilead Sciences Company Information Table 85. Gilead Sciences Business Overview Table 86. Gilead Sciences Tumor Radioimmunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 87. Gilead Sciences Tumor Radioimmunotherapy Product Portfolio Table 88. Gilead Sciences Recent Development Table 89. Fusion Pharmaceuticals Company Information Table 90. Fusion Pharmaceuticals Business Overview Table 91. Fusion Pharmaceuticals Tumor Radioimmunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 92. Fusion Pharmaceuticals Tumor Radioimmunotherapy Product Portfolio Table 93. Fusion Pharmaceuticals Recent Development Table 94. Curium Pharmaceuticals Company Information Table 95. Curium Pharmaceuticals Business Overview Table 96. Curium Pharmaceuticals Tumor Radioimmunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 97. Curium Pharmaceuticals Tumor Radioimmunotherapy Product Portfolio Table 98. Curium Pharmaceuticals Recent Development Table 99. Curasight Company Information Table 100. Curasight Business Overview Table 101. Curasight Tumor Radioimmunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 102. Curasight Tumor Radioimmunotherapy Product Portfolio Table 103. Curasight Recent Development Table 104. Clarity Pharmaceuticals Company Information Table 105. Clarity Pharmaceuticals Business Overview Table 106. Clarity Pharmaceuticals Tumor Radioimmunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 107. Clarity Pharmaceuticals Tumor Radioimmunotherapy Product Portfolio Table 108. Clarity Pharmaceuticals Recent Development Table 109. China Isotope & Radiation Company Information Table 110. China Isotope & Radiation Business Overview Table 111. China Isotope & Radiation Tumor Radioimmunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 112. China Isotope & Radiation Tumor Radioimmunotherapy Product Portfolio Table 113. China Isotope & Radiation Recent Development Table 114. Aurobindo Pharma Company Information Table 115. Aurobindo Pharma Business Overview Table 116. Aurobindo Pharma Tumor Radioimmunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 117. Aurobindo Pharma Tumor Radioimmunotherapy Product Portfolio Table 118. Aurobindo Pharma Recent Development Table 119. Actinium Pharmaceuticals Company Information Table 120. Actinium Pharmaceuticals Business Overview Table 121. Actinium Pharmaceuticals Tumor Radioimmunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 122. Actinium Pharmaceuticals Tumor Radioimmunotherapy Product Portfolio Table 123. Actinium Pharmaceuticals Recent Development Table 124. North America Tumor Radioimmunotherapy Market Size by Type (2021-2026) & (US$ Million) Table 125. North America Tumor Radioimmunotherapy Market Size by Type (2027-2032) & (US$ Million) Table 126. North America Tumor Radioimmunotherapy Market Size by Application (2021-2026) & (US$ Million) Table 127. North America Tumor Radioimmunotherapy Market Size by Application (2027-2032) & (US$ Million) Table 128. North America Tumor Radioimmunotherapy Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 129. North America Tumor Radioimmunotherapy Market Size by Country (2021-2026) Table 130. North America Tumor Radioimmunotherapy Market Size by Country (2027-2032) Table 131. Europe Tumor Radioimmunotherapy Market Size by Type (2021-2026) & (US$ Million) Table 132. Europe Tumor Radioimmunotherapy Market Size by Type (2027-2032) & (US$ Million) Table 133. Europe Tumor Radioimmunotherapy Market Size by Application (2021-2026) & (US$ Million) Table 134. Europe Tumor Radioimmunotherapy Market Size by Application (2027-2032) & (US$ Million) Table 135. Europe Tumor Radioimmunotherapy Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 136. Europe Tumor Radioimmunotherapy Market Size by Country (2021-2026) Table 137. Europe Tumor Radioimmunotherapy Market Size by Country (2027-2032) Table 138. China Tumor Radioimmunotherapy Market Size by Type (2021-2026) & (US$ Million) Table 139. China Tumor Radioimmunotherapy Market Size by Type (2027-2032) & (US$ Million) Table 140. China Tumor Radioimmunotherapy Market Size by Application (2021-2026) & (US$ Million) Table 141. China Tumor Radioimmunotherapy Market Size by Application (2027-2032) & (US$ Million) Table 142. Asia Tumor Radioimmunotherapy Market Size by Type (2021-2026) & (US$ Million) Table 143. Asia Tumor Radioimmunotherapy Market Size by Type (2027-2032) & (US$ Million) Table 144. Asia Tumor Radioimmunotherapy Market Size by Application (2021-2026) & (US$ Million) Table 145. Asia Tumor Radioimmunotherapy Market Size by Application (2027-2032) & (US$ Million) Table 146. Asia Tumor Radioimmunotherapy Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 147. Asia Tumor Radioimmunotherapy Market Size by Country (2021-2026) Table 148. Asia Tumor Radioimmunotherapy Market Size by Country (2027-2032) Table 149. South America, Middle East & Africa Tumor Radioimmunotherapy Market Size by Type (2021-2026) & (US$ Million) Table 150. South America, Middle East & Africa Tumor Radioimmunotherapy Market Size by Type (2027-2032) & (US$ Million) Table 151. South America, Middle East & Africa Tumor Radioimmunotherapy Market Size by Application (2021-2026) & (US$ Million) Table 152. South America, Middle East & Africa Tumor Radioimmunotherapy Market Size by Application (2027-2032) & (US$ Million) Table 153. South America, Middle East & Africa Tumor Radioimmunotherapy Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 154. South America, Middle East & Africa Tumor Radioimmunotherapy Market Size by Country (2021-2026) Table 155. South America, Middle East & Africa Tumor Radioimmunotherapy Market Size by Country (2027-2032) Table 156. Research Programs/Design for This Report Table 157. Authors List of This Report Table 158. Secondary Sources Table 159. Primary Sources List of Figures Figure 1. Tumor Radioimmunotherapy Product Image Figure 2. Global Tumor Radioimmunotherapy Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Tumor Radioimmunotherapy Market Share by Type: 2025 VS 2032 Figure 4. Beta-emitting Image Figure 5. Targeted Alpha Therapy Image Figure 6. Global Tumor Radioimmunotherapy Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 7. Global Tumor Radioimmunotherapy Market Share by Application: 2025 VS 2032 Figure 8. Solid Tumor Image Figure 9. Non Hodgkin Lymphoma Image Figure 10. Global Tumor Radioimmunotherapy Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global Tumor Radioimmunotherapy Market Size (2021-2032) & (US$ Million) Figure 12. Global Tumor Radioimmunotherapy Market Share by Region: 2025 VS 2032 Figure 13. Years Considered Figure 14. Global Tumor Radioimmunotherapy Market Share by Players in 2025 Figure 15. Global Top 5 and 10 Tumor Radioimmunotherapy Players Market Share by Revenue in 2025 Figure 16. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Tumor Radioimmunotherapy Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Tumor Radioimmunotherapy Revenue Market Share by Type (2021-2032) Figure 19. Global Tumor Radioimmunotherapy Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Tumor Radioimmunotherapy Revenue Market Share by Application (2021-2032) Figure 21. North America Tumor Radioimmunotherapy Market Size (2021-2032) & (US$ Million) Figure 22. North America Tumor Radioimmunotherapy Market Share by Type (2021-2032) Figure 23. North America Tumor Radioimmunotherapy Market Share by Application (2021-2032) Figure 24. North America Tumor Radioimmunotherapy Market Share by Country (2021-2032) Figure 25. United States Tumor Radioimmunotherapy Market Size (2021-2032) & (US$ Million) Figure 26. Canada Tumor Radioimmunotherapy Market Size (2021-2032) & (US$ Million) Figure 27. Mexico Tumor Radioimmunotherapy Market Size (2021-2032) & (US$ Million) Figure 28. Europe Tumor Radioimmunotherapy Market Size (2021-2032) & (US$ Million) Figure 29. Europe Tumor Radioimmunotherapy Market Share by Type (2021-2032) Figure 30. Europe Tumor Radioimmunotherapy Market Share by Application (2021-2032) Figure 31. Europe Tumor Radioimmunotherapy Market Share by Country (2021-2032) Figure 32. Germany Tumor Radioimmunotherapy Market Size (2021-2032) & (US$ Million) Figure 33. France Tumor Radioimmunotherapy Market Size (2021-2032) & (US$ Million) Figure 34. U.K. Tumor Radioimmunotherapy Market Size (2021-2032) & (US$ Million) Figure 35. Italy Tumor Radioimmunotherapy Market Size (2021-2032) & (US$ Million) Figure 36. Russia Tumor Radioimmunotherapy Market Size (2021-2032) & (US$ Million) Figure 37. Nordic Countries Tumor Radioimmunotherapy Market Size (2021-2032) & (US$ Million) Figure 38. China Tumor Radioimmunotherapy Market Size (2021-2032) & (US$ Million) Figure 39. China Tumor Radioimmunotherapy Market Share by Type (2021-2032) Figure 40. China Tumor Radioimmunotherapy Market Share by Application (2021-2032) Figure 41. Asia Tumor Radioimmunotherapy Market Size (2021-2032) & (US$ Million) Figure 42. Asia Tumor Radioimmunotherapy Market Share by Type (2021-2032) Figure 43. Asia Tumor Radioimmunotherapy Market Share by Application (2021-2032) Figure 44. Asia Tumor Radioimmunotherapy Market Share by Country (2021-2032) Figure 45. Japan Tumor Radioimmunotherapy Market Size (2021-2032) & (US$ Million) Figure 46. South Korea Tumor Radioimmunotherapy Market Size (2021-2032) & (US$ Million) Figure 47. Taiwan Tumor Radioimmunotherapy Market Size (2021-2032) & (US$ Million) Figure 48. Southeast Asia Tumor Radioimmunotherapy Market Size (2021-2032) & (US$ Million) Figure 49. India Tumor Radioimmunotherapy Market Size (2021-2032) & (US$ Million) Figure 50. Australia Tumor Radioimmunotherapy Market Size (2021-2032) & (US$ Million) Figure 51. South America, Middle East & Africa Tumor Radioimmunotherapy Market Size (2021-2032) & (US$ Million) Figure 52. South America, Middle East & Africa Tumor Radioimmunotherapy Market Share by Type (2021-2032) Figure 53. South America, Middle East & Africa Tumor Radioimmunotherapy Market Share by Application (2021-2032) Figure 54. South America, Middle East & Africa Tumor Radioimmunotherapy Market Share by Country (2021-2032) Figure 55. Brazil Tumor Radioimmunotherapy Market Size (2021-2032) & (US$ Million) Figure 56. South Africa Tumor Radioimmunotherapy Market Size (2021-2032) & (US$ Million) Figure 57. Saudi Arabia Tumor Radioimmunotherapy Market Size (2021-2032) & (US$ Million) Figure 58. Turkey Tumor Radioimmunotherapy Market Size (2021-2032) & (US$ Million) Figure 59. Argentina Tumor Radioimmunotherapy Market Size (2021-2032) & (US$ Million) Figure 60. UAE Tumor Radioimmunotherapy Market Size (2021-2032) & (US$ Million) Figure 61. Egypt Tumor Radioimmunotherapy Market Size (2021-2032) & (US$ Million) Figure 62. Chile Tumor Radioimmunotherapy Market Size (2021-2032) & (US$ Million) Figure 63. Research Process Figure 64. Key Executives Interviewed

Scope & coverage.

Types
  • Beta-emitting
  • Targeted Alpha Therapy
Applications
  • Solid Tumor
  • Non Hodgkin Lymphoma
Companies covered
  • Novartis
  • Bayer
  • Y-mAbs Therapeutics
  • Telix Pharmaceuticals
  • RadioMedix
  • Philogen
  • Orano Med
  • Nordic Nanovector
  • Mundipharma
  • Lantheus
  • Gilead Sciences
  • Fusion Pharmaceuticals
  • Curium Pharmaceuticals
  • Curasight
  • Clarity Pharmaceuticals
  • China Isotope & Radiation
  • Aurobindo Pharma
  • Actinium Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Tumor Radioimmunotherapy Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Beta-emitting
  5. 1.2.3 Targeted Alpha Therapy
  6. 1.3 Market Analysis by Application
  7. 1.3.1 Global Tumor Radioimmunotherapy Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  8. 1.3.2 Solid Tumor
  9. 1.3.3 Non Hodgkin Lymphoma
  10. 1.4 Global Market Growth Prospects
  11. 1.5 Global Tumor Radioimmunotherapy Growth Trends by Region
  12. 1.5.1 Global Tumor Radioimmunotherapy Market Size by Region: 2021 VS 2025 VS 2032
  13. 1.5.2 Tumor Radioimmunotherapy Market Size by Region (2021-2026)
  14. 1.5.3 Tumor Radioimmunotherapy Market Size by Region (2027-2032)
  15. 1.6 Assumptions and Limitations
  16. 1.7 Study Goals and Objectives
  17. 1.8 Years Considered
2 Global Tumor Radioimmunotherapy Market Dynamics
  1. 2.1 Tumor Radioimmunotherapy Industry Trends
  2. 2.2 Tumor Radioimmunotherapy Industry Drivers
  3. 2.3 Tumor Radioimmunotherapy Industry Opportunities and Challenges
  4. 2.4 Tumor Radioimmunotherapy Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Tumor Radioimmunotherapy Revenue by Company (2021-2026)
  2. 3.2 Global Tumor Radioimmunotherapy Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Tumor Radioimmunotherapy Key Company Head office and Area Served
  4. 3.4 Global Tumor Radioimmunotherapy Company, Product Type & Application
  5. 3.5 Global Tumor Radioimmunotherapy Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Tumor Radioimmunotherapy Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Tumor Radioimmunotherapy Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Tumor Radioimmunotherapy Tier 1, Tier 2, and Tier 3
4 Tumor Radioimmunotherapy Market by Type
  1. 4.1 Global Tumor Radioimmunotherapy Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Tumor Radioimmunotherapy Market Size by Type (2021-2032)
  3. 4.3 Global Tumor Radioimmunotherapy Market Size Share by Type (2021-2032)
5 Tumor Radioimmunotherapy Market by Application
  1. 5.1 Global Tumor Radioimmunotherapy Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Tumor Radioimmunotherapy Market Size by Application (2021-2032)
  3. 5.3 Global Tumor Radioimmunotherapy Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Novartis
  2. 6.1.1 Novartis Company Information
  3. 6.1.2 Novartis Business Overview
  4. 6.1.3 Novartis Tumor Radioimmunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Novartis Tumor Radioimmunotherapy Product Portfolio
  6. 6.1.5 Novartis Recent Developments
  7. 6.2 Bayer
  8. 6.2.1 Bayer Company Information
  9. 6.2.2 Bayer Business Overview
  10. 6.2.3 Bayer Tumor Radioimmunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Bayer Tumor Radioimmunotherapy Product Portfolio
  12. 6.2.5 Bayer Recent Developments
  13. 6.3 Y-mAbs Therapeutics
  14. 6.3.1 Y-mAbs Therapeutics Company Information
  15. 6.3.2 Y-mAbs Therapeutics Business Overview
  16. 6.3.3 Y-mAbs Therapeutics Tumor Radioimmunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Y-mAbs Therapeutics Tumor Radioimmunotherapy Product Portfolio
  18. 6.3.5 Y-mAbs Therapeutics Recent Developments
  19. 6.4 Telix Pharmaceuticals
  20. 6.4.1 Telix Pharmaceuticals Company Information
  21. 6.4.2 Telix Pharmaceuticals Business Overview
  22. 6.4.3 Telix Pharmaceuticals Tumor Radioimmunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Telix Pharmaceuticals Tumor Radioimmunotherapy Product Portfolio
  24. 6.4.5 Telix Pharmaceuticals Recent Developments
  25. 6.5 RadioMedix
  26. 6.5.1 RadioMedix Company Information
  27. 6.5.2 RadioMedix Business Overview
  28. 6.5.3 RadioMedix Tumor Radioimmunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 RadioMedix Tumor Radioimmunotherapy Product Portfolio
  30. 6.5.5 RadioMedix Recent Developments
  31. 6.6 Philogen
  32. 6.6.1 Philogen Company Information
  33. 6.6.2 Philogen Business Overview
  34. 6.6.3 Philogen Tumor Radioimmunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Philogen Tumor Radioimmunotherapy Product Portfolio
  36. 6.6.5 Philogen Recent Developments
  37. 6.7 Orano Med
  38. 6.7.1 Orano Med Company Information
  39. 6.7.2 Orano Med Business Overview
  40. 6.7.3 Orano Med Tumor Radioimmunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Orano Med Tumor Radioimmunotherapy Product Portfolio
  42. 6.7.5 Orano Med Recent Developments
  43. 6.8 Nordic Nanovector
  44. 6.8.1 Nordic Nanovector Company Information
  45. 6.8.2 Nordic Nanovector Business Overview
  46. 6.8.3 Nordic Nanovector Tumor Radioimmunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Nordic Nanovector Tumor Radioimmunotherapy Product Portfolio
  48. 6.8.5 Nordic Nanovector Recent Developments
  49. 6.9 Mundipharma
  50. 6.9.1 Mundipharma Company Information
  51. 6.9.2 Mundipharma Business Overview
  52. 6.9.3 Mundipharma Tumor Radioimmunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 Mundipharma Tumor Radioimmunotherapy Product Portfolio
  54. 6.9.5 Mundipharma Recent Developments
  55. 6.10 Lantheus
  56. 6.10.1 Lantheus Company Information
  57. 6.10.2 Lantheus Business Overview
  58. 6.10.3 Lantheus Tumor Radioimmunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 Lantheus Tumor Radioimmunotherapy Product Portfolio
  60. 6.10.5 Lantheus Recent Developments
  61. 6.11 Gilead Sciences
  62. 6.11.1 Gilead Sciences Company Information
  63. 6.11.2 Gilead Sciences Business Overview
  64. 6.11.3 Gilead Sciences Tumor Radioimmunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026)
  65. 6.11.4 Gilead Sciences Tumor Radioimmunotherapy Product Portfolio
  66. 6.11.5 Gilead Sciences Recent Developments
  67. 6.12 Fusion Pharmaceuticals
  68. 6.12.1 Fusion Pharmaceuticals Company Information
  69. 6.12.2 Fusion Pharmaceuticals Business Overview
  70. 6.12.3 Fusion Pharmaceuticals Tumor Radioimmunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026)
  71. 6.12.4 Fusion Pharmaceuticals Tumor Radioimmunotherapy Product Portfolio
  72. 6.12.5 Fusion Pharmaceuticals Recent Developments
  73. 6.13 Curium Pharmaceuticals
  74. 6.13.1 Curium Pharmaceuticals Company Information
  75. 6.13.2 Curium Pharmaceuticals Business Overview
  76. 6.13.3 Curium Pharmaceuticals Tumor Radioimmunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026)
  77. 6.13.4 Curium Pharmaceuticals Tumor Radioimmunotherapy Product Portfolio
  78. 6.13.5 Curium Pharmaceuticals Recent Developments
  79. 6.14 Curasight
  80. 6.14.1 Curasight Company Information
  81. 6.14.2 Curasight Business Overview
  82. 6.14.3 Curasight Tumor Radioimmunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026)
  83. 6.14.4 Curasight Tumor Radioimmunotherapy Product Portfolio
  84. 6.14.5 Curasight Recent Developments
  85. 6.15 Clarity Pharmaceuticals
  86. 6.15.1 Clarity Pharmaceuticals Company Information
  87. 6.15.2 Clarity Pharmaceuticals Business Overview
  88. 6.15.3 Clarity Pharmaceuticals Tumor Radioimmunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026)
  89. 6.15.4 Clarity Pharmaceuticals Tumor Radioimmunotherapy Product Portfolio
  90. 6.15.5 Clarity Pharmaceuticals Recent Developments
  91. 6.16 China Isotope & Radiation
  92. 6.16.1 China Isotope & Radiation Company Information
  93. 6.16.2 China Isotope & Radiation Business Overview
  94. 6.16.3 China Isotope & Radiation Tumor Radioimmunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026)
  95. 6.16.4 China Isotope & Radiation Tumor Radioimmunotherapy Product Portfolio
  96. 6.16.5 China Isotope & Radiation Recent Developments
  97. 6.17 Aurobindo Pharma
  98. 6.17.1 Aurobindo Pharma Company Information
  99. 6.17.2 Aurobindo Pharma Business Overview
  100. 6.17.3 Aurobindo Pharma Tumor Radioimmunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026)
  101. 6.17.4 Aurobindo Pharma Tumor Radioimmunotherapy Product Portfolio
  102. 6.17.5 Aurobindo Pharma Recent Developments
  103. 6.18 Actinium Pharmaceuticals
  104. 6.18.1 Actinium Pharmaceuticals Company Information
  105. 6.18.2 Actinium Pharmaceuticals Business Overview
  106. 6.18.3 Actinium Pharmaceuticals Tumor Radioimmunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026)
  107. 6.18.4 Actinium Pharmaceuticals Tumor Radioimmunotherapy Product Portfolio
  108. 6.18.5 Actinium Pharmaceuticals Recent Developments
7 North America
  1. 7.1 North America Tumor Radioimmunotherapy Market Size (2021-2032)
  2. 7.2 North America Tumor Radioimmunotherapy Market Size by Type
  3. 7.2.1 North America Tumor Radioimmunotherapy Market Size by Type (2021-2026)
  4. 7.2.2 North America Tumor Radioimmunotherapy Market Size by Type (2027-2032)
  5. 7.2.3 North America Tumor Radioimmunotherapy Market Share by Type (2021-2032)
  6. 7.3 North America Tumor Radioimmunotherapy Market Size by Application
  7. 7.3.1 North America Tumor Radioimmunotherapy Market Size by Application (2021-2026)
  8. 7.3.2 North America Tumor Radioimmunotherapy Market Size by Application (2027-2032)
  9. 7.3.3 North America Tumor Radioimmunotherapy Market Share by Application (2021-2032)
  10. 7.4 North America Tumor Radioimmunotherapy Market Size by Country
  11. 7.4.1 North America Tumor Radioimmunotherapy Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Tumor Radioimmunotherapy Market Size by Country (2021-2026)
  13. 7.4.3 North America Tumor Radioimmunotherapy Market Size by Country (2027-2032)
  14. 7.4.4 North America Tumor Radioimmunotherapy Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Tumor Radioimmunotherapy Market Size (2021-2032)
  2. 8.2 Europe Tumor Radioimmunotherapy Market Size by Type
  3. 8.2.1 Europe Tumor Radioimmunotherapy Market Size by Type (2021-2026)
  4. 8.2.2 Europe Tumor Radioimmunotherapy Market Size by Type (2027-2032)
  5. 8.2.3 Europe Tumor Radioimmunotherapy Market Share by Type (2021-2032)
  6. 8.3 Europe Tumor Radioimmunotherapy Market Size by Application
  7. 8.3.1 Europe Tumor Radioimmunotherapy Market Size by Application (2021-2026)
  8. 8.3.2 Europe Tumor Radioimmunotherapy Market Size by Application (2027-2032)
  9. 8.3.3 Europe Tumor Radioimmunotherapy Market Share by Application (2021-2032)
  10. 8.4 Europe Tumor Radioimmunotherapy Market Size by Country
  11. 8.4.1 Europe Tumor Radioimmunotherapy Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Tumor Radioimmunotherapy Market Size by Country (2021-2026)
  13. 8.4.3 Europe Tumor Radioimmunotherapy Market Size by Country (2027-2032)
  14. 8.4.4 Europe Tumor Radioimmunotherapy Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Tumor Radioimmunotherapy Market Size (2021-2032)
  2. 9.2 China Tumor Radioimmunotherapy Market Size by Type
  3. 9.2.1 China Tumor Radioimmunotherapy Market Size by Type (2021-2026)
  4. 9.2.2 China Tumor Radioimmunotherapy Market Size by Type (2027-2032)
  5. 9.2.3 China Tumor Radioimmunotherapy Market Share by Type (2021-2032)
  6. 9.3 China Tumor Radioimmunotherapy Market Size by Application
  7. 9.3.1 China Tumor Radioimmunotherapy Market Size by Application (2021-2026)
  8. 9.3.2 China Tumor Radioimmunotherapy Market Size by Application (2027-2032)
  9. 9.3.3 China Tumor Radioimmunotherapy Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Tumor Radioimmunotherapy Market Size (2021-2032)
  2. 10.2 Asia Tumor Radioimmunotherapy Market Size by Type
  3. 10.2.1 Asia Tumor Radioimmunotherapy Market Size by Type (2021-2026)
  4. 10.2.2 Asia Tumor Radioimmunotherapy Market Size by Type (2027-2032)
  5. 10.2.3 Asia Tumor Radioimmunotherapy Market Share by Type (2021-2032)
  6. 10.3 Asia Tumor Radioimmunotherapy Market Size by Application
  7. 10.3.1 Asia Tumor Radioimmunotherapy Market Size by Application (2021-2026)
  8. 10.3.2 Asia Tumor Radioimmunotherapy Market Size by Application (2027-2032)
  9. 10.3.3 Asia Tumor Radioimmunotherapy Market Share by Application (2021-2032)
  10. 10.4 Asia Tumor Radioimmunotherapy Market Size by Country
  11. 10.4.1 Asia Tumor Radioimmunotherapy Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Tumor Radioimmunotherapy Market Size by Country (2021-2026)
  13. 10.4.3 Asia Tumor Radioimmunotherapy Market Size by Country (2027-2032)
  14. 10.4.4 Asia Tumor Radioimmunotherapy Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Tumor Radioimmunotherapy Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Tumor Radioimmunotherapy Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Tumor Radioimmunotherapy Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Tumor Radioimmunotherapy Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Tumor Radioimmunotherapy Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Tumor Radioimmunotherapy Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Tumor Radioimmunotherapy Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Tumor Radioimmunotherapy Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Tumor Radioimmunotherapy Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Tumor Radioimmunotherapy Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Tumor Radioimmunotherapy Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Tumor Radioimmunotherapy Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Tumor Radioimmunotherapy Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Tumor Radioimmunotherapy Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst